Experiences in treatment of multiple sclerosis with betaferon in federation of Bosnia and Herzegovina.
Multiple sclerosis is an insidious, intermittent or chronic progressive inflammatory, autoimmune disease of the central nervous system; it is a major cause of disability, especially in young adults. It affects women twice as often as men. The prevalence varies from 50 to 100 per 100,000 in moderate climate zones. Interferon beta-1b reduces frequency and severity of clinical attacks of relapsing-remitting multiple sclerosis and prolonged time until the progression of disability and time patients suffering from secondary progressive multiple sclerosis become wheelchair-bound.
Mehmedika-Suljic
Enra
E
Commission for Multiple Sclerosis Treatment, Institute for Health Insurance, Federation Bosnia and Herzegovina. enra@lol.ba
Burza-Bosnjak
Ela
E
Bera
Marina
M
Hasovic
Mustafa
M
Sinanovic
Osman
O
D000276:Adjuvants, Immunologic / Q000627:therapeutic use*; D000328:Adult; D005260:Female; D006801:Humans; D000068576:Interferon beta-1b; D016899:Interferon-beta / Q000627:therapeutic use*; D008297:Male; D020529:Multiple Sclerosis, Relapsing-Remitting / Q000188:drug therapy*; D011994:Recombinant Proteins / Q000627:therapeutic use
D000276:Adjuvants, Immunologic; D011994:Recombinant Proteins; D000068576:Interferon beta-1b; D016899:Interferon-beta